Clinical Trials Logo

Glioma clinical trials

View clinical trials related to Glioma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06199388 Completed - Glioma Clinical Trials

Development and Validation of a Deep Learning-Based Survival Prediction Model for Pediatric Glioma Patients: A Retrospective Study Using the SEER Database and Chinese Data

Start date: September 20, 2022
Phase:
Study type: Observational

Accurately predicting the survival of pediatric glioma patients is crucial for informed clinical decision-making and selecting appropriate treatment strategies. However, there is a lack of prognostic models specifically tailored for pediatric glioma patients. This study aimed to address this gap by developing a time-dependent deep learning model to aid physicians in making more accurate prognostic assessments and treatment decisions.

NCT ID: NCT05896449 Completed - Glioma, Malignant Clinical Trials

Predictive Values of Preoperative [68Ga]Ga-PSMA-11 PET/CT in Patients With Suspected Brain Tumours of Glial Origin

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

The aim of this study was to analyse usefulness of [68Ga]Ga-PSMA-11 PET/CT scans in preoperative differentiation between HGG and LGG in patients with suspicion of a tumor of glial origin in previously performed imaging examinations. The PET/CT scan will be compared with postoperative histopathological results and with additional immunohistochemical staining for PSMA expression.

NCT ID: NCT05873946 Completed - Glioblastoma Clinical Trials

Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery

2D-ioUS-Glio
Start date: June 1, 2018
Phase:
Study type: Observational

This retrospective study aims to assess the utility of 2D non-navigated intraoperative ultrasound (ioUS) as a cost-effective alternative for guiding the surgical resection of gliomas and for detecting residual tumor. The study will analyse the records from consecutive adult patients diagnosed with gliomas, undergoing craniotomy between June 2018 and June 2023. The extent of resection (EOR) will be determined using postoperative MRI as the gold standard. The study will also examine the sensitivity and specificity of ioUS in detecting residual tumor. This research seeks to determine if ioUS can be an affordable and reliable tool that, combined with other intraoperative adjuncts, may aid neurosurgeons in achieving the maximum safe resection in glioma surgery.

NCT ID: NCT05806619 Completed - Glioma, Malignant Clinical Trials

Glioma: Biomolecular Aspects

GLIOMA
Start date: October 22, 2019
Phase:
Study type: Observational [Patient Registry]

Main limitations in Glioma studies are due to the wide heterogeneity and genetic instability of the tumor and to the fact that the molecular informations are static, i.e. obtained on the tumor at its onset. Instead, spontaneous or therapy-induced variations are difficult to evaluate and they would need further sampling of the tumor throughout the clinical history. Currently these data are more and more routinely used not only for diagnostics but also in the clinical management of the patient. Furthermore, microenvironment study is becoming increasingly important. It is also important correlate morpho-functional pathway and brain Magnetic Resonance. Therefore, the main goal of the study is to correlate the data obtained with morphological (site, signal intensity, margins, behavior after contrast medium infusion, mismatch between T2 and FLAIR sequences) and non-morphological MR imaging through a radiomic approach and Diffusion and Perfusion study, with molecular data relating to the IDH mutation, MGMT gene promoter methylation, 1p/19q co-deletion and EGFRvIII expression. Furthermore, it is proposed to carry out a correlation between the radiological data and the mutations found in the NGS panel.

NCT ID: NCT05604365 Completed - Glioma Clinical Trials

FearLess in Cognitively Intact Patients With Glioma

FearLess
Start date: November 7, 2022
Phase: N/A
Study type: Interventional

This study will assess the preliminary feasibility and acceptability of FearLess, a newly-developed psychological intervention for fear of cancer recurrence (FCR) among cognitively-intact patients with glioma.

NCT ID: NCT05486247 Completed - Malignant Glioma Clinical Trials

Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel

Start date: February 4, 2015
Phase:
Study type: Observational

Gliomas are the most common malignant primary brain tumors with poor prognosis. The genotyping of tumors using NGS platforms enables the identification of genetic alterations that constitute diagnostic, prognostic and predictive biomarkers.Here in, we investigated the molecular profile of 32 tumor samples from 32 patients with high grade gliomas by implementing a broad 80-gene targeted NGS panel while reporting their clinicopathological characteristics and outcomes.

NCT ID: NCT05373394 Completed - Motor Disorders Clinical Trials

Evaluation of Cognitive and Motor Neurological Disorders in the Short and Long Term After Surgery for the Removal of a Diffuse Low-grade Glioma of the Supplementary Motor Area

POG-C
Start date: May 19, 2022
Phase:
Study type: Observational

Background : The supplementary motor area is the most common/preferential brain location of LGG. This area plays an important role in many motor and cognitive functions such as motor initiation, bimanual coordination and executive functions. Many studies describe the supplementary motor area syndrome resulting from lesions in this area. News managements for LGGs consisting in intraoperative mapping in awake patients reduce significantly neurological disorders and increase also the overall survival . However, the literature does not provide data concerning motor and cognitive functions in a long term and their consequences in the quality of life of patients. Objective : The aim of our research project is to identify whether there are some motor or neurocognitive deficit in the short and the long term in a population of patients who have medical story of LGG resection in the supplementary motor area.

NCT ID: NCT05100602 Completed - Glioma, Malignant Clinical Trials

Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients

Start date: May 13, 2016
Phase:
Study type: Observational

The purpose of this trail is to evaluate the performance of Genetron TERT PCR Kit in Glioma patients using real-time PCR method.

NCT ID: NCT05100173 Completed - Glioma, Malignant Clinical Trials

Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients

Start date: May 13, 2016
Phase:
Study type: Observational

The purpose of this trail is to evaluate the performance of Genetron IDH1 PCR Kit in Glioma patients using real-time PCR method.

NCT ID: NCT05039346 Completed - Quality of Life Clinical Trials

Quality of Life and Patient Needs in Advanced High Grade Gliomas

Start date: February 11, 2012
Phase:
Study type: Observational

There is limited knowledge regarding the quality of life and needs of patients with advanced high grade gliomas, especially during the end of life. By doing this research, we are able to assess caregiver and patient symptoms and needs during the end of life phase of patients with brain tumors.